Clinical Trial Update: Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating NIS793 with or without spartalizumab in combination with standard-of-care chemotherapy for first-line metastatic pancreatic ductal aden…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• NIS793 (NIS-793)
• Spartalizumab (spartalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2025-05-28